Richard E Yeager

Title: Richard E Yeager: Innovator in Psychotropic Compounds

Introduction

Richard E Yeager is a notable inventor based in Evansville, IN (US). He has made significant contributions to the field of psychotropic compounds, holding a total of 2 patents. His work focuses on developing innovative derivatives that exhibit selective psychotropic properties.

Latest Patents

Yeager's latest patents include the development of spirothiazolidinyl piperazine derivatives. These compounds contain a spiro-2,4-thiazolidinedione heterocyclic component, which has been shown to possess relatively selective psychotropic properties. One of the key embodiments of this invention is the compound 2-[4-[4-(7,9-dioxo-6-thia-8-azaspiro[4.4]nonan-8-yl)butyl]-1-piperazinyl]pyridine-3-carbonitrile, which demonstrates selective anti-psychotic activity. Another significant patent involves thiazolidinylalkylene piperazine derivatives. These derivatives contain a 3-alkylene-2,4-thiazolidinedione heterocyclic component, also exhibiting selective psychotropic properties. A typical embodiment of this invention is the compound 3-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,4-thiazolidinedione, which has shown selective anxiolytic activity.

Career Highlights

Richard E Yeager is currently associated with Mead Johnson & Company, where he continues to innovate in the field of psychotropic compounds. His work has contributed to advancements in the understanding and treatment of various psychological conditions.

Collaborations

Yeager collaborates with Davis L Temple, Jr., enhancing the research and development efforts within their field. Their combined expertise fosters innovation and the exploration of new therapeutic avenues.

Conclusion

Richard E Yeager's contributions to the field of psychotropic compounds highlight his role as an influential inventor. His patents reflect a commitment to advancing mental health treatments through innovative chemical compounds.